42
5.42 Clinical Experience of Berinert
®
in Abdominal Attacks
In an intraindividual retrospective comparison in 75 HAE
patients, 4,834 abdominal attacks treated with Berinert
®
were compared with 17,444 untreated abdominal attacks.
83
•
Mean duration of attacks was 39.9 hours
(SD =30.0 hours) with Berinert
®
therapy vs
92 hours (SD = 40.8 hours) without treatment.
•
Maximal pain as rated by the patients on a scale of
1 to 10 (1 = very mild pain; 10 = extremely severe,
unbearable pain) was distinctly lower in the
Berinert
®
-treated HAE episodes (4.5) than in the
untreated ones (8.6).
•
Vomiting occurred in 6% of the treated attacks vs
83.3% of the untreated attacks.
•
Diarrhea occurred in only 11% of the treated
episodes vs 41.8% of the untreated episodes.
•
Hypovolemia-related circulatory collapse was
observed in only 0.1% of the HAE attacks treated
with Berinert
®
vs 3.5% of the untreated attacks.
5.43 Clinical Experience of Berinert
®
in Laryngeal Attacks
In a retrospective collection of case data on the treatment
of HAE patients who suffered from laryngeal edema, the
patients who had received Berinert
®
were compared with
historical controls that had not received C1-INH concentrate.
Overall, 18 patients received 500 or 1,000 IU Berinert
®
during 193 laryngeal episodes. Berinert
®
was effective in
all patients.
39
•
Mean onset of symptom improvement was
42.2 minutes (SD =19.9 minutes).
•
Mean time to complete regression of the symptoms
was 15.3 hours (SD =9.3 hours) in the Berinert
®
-
treated patients vs 100.8 hours (SD =26.2 hours)
in the control group.
